Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $1.5 billion.

  • Neurocrine Biosciences' Cash & Current Investments rose 3757.09% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 3757.09%. This contributed to the annual value of $1.5 billion for FY2025, which is 3757.09% up from last year.
  • Neurocrine Biosciences' Cash & Current Investments amounted to $1.5 billion in Q4 2025, which was up 3757.09% from $1.1 billion recorded in Q3 2025.
  • Neurocrine Biosciences' Cash & Current Investments' 5-year high stood at $1.5 billion during Q4 2025, with a 5-year trough of $765.9 million in Q3 2021.
  • For the 4-year period, Neurocrine Biosciences' Cash & Current Investments averaged around $1.0 billion, with its median value being $1.0 billion (2024).
  • Within the past 5 years, the most significant YoY rise in Neurocrine Biosciences' Cash & Current Investments was 3757.09% (2025), while the steepest drop was 2206.34% (2025).
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Cash & Current Investments stood at $765.9 million in 2021, then skyrocketed by 35.74% to $1.0 billion in 2023, then rose by 3.51% to $1.1 billion in 2024, then surged by 37.57% to $1.5 billion in 2025.
  • Its Cash & Current Investments was $1.5 billion in Q4 2025, compared to $1.1 billion in Q3 2025 and $975.6 million in Q2 2025.